While SCARB1 is a complex therapeutic target, the effect of SSO8.3 in decreasing the amounts of some of these lipid species in hepatocytes indicates that strategies aimed to promote the SR-BII isoform could contribute to alleviating obesity-induced inflammation in vivo. Here, SCARB2 is linked to Obesity.